OBIO - NASDAQ
Orchestra BioMed Holdings, Inc.
$3.86
-0.52%Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
At a Glance
Live SnapshotOrchestra BioMed Holdings, Inc. Management Team
Dr. Hans-Peter Stoll M.D., Ph.D.
Chief Clinical Officer
Mr. Andrew Lawrence Taylor M.B.A.
Chief Financial Officer
Compensation
$562,409
Mr. William Reed Little
Executive Vice President of Corporate Development & Strategy
Mr. David P. Hochman
Founder, Chairman of the Board of Directors & Chief Executive Officer
Compensation
$916,475
Mr. Darren R. Sherman
Founder, President, Chief Operating Officer & Director
Compensation
$914,475
Dr. Yuval Hay Mika D.Sc, Ph.D.
GM & Chief Technology Officer of Bioelectronic Therapies
Mr. Mark Pomeranz
GM & Executive Vice President of Interventional Therapies
Dr. Avraham Matityahu Fischer M.D.
Senior Vice President of Medical Affairs & Innovation
Mr. Juan Lorenzo
Senior Vice President of Product Development
Mr. Bob Laughner
Senior Vice President of Regulatory & Quality
Orchestra BioMed Holdings, Inc. Insider Positioning
During the last 12 months, insiders have purchased $559K and sold $332K worth of OBIO shares, resulting in $227K of net buying activity.
3 Months
49.6K
200.98K
15.0K
58.18K
+143K
+$143K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
6.0K
22.80K
19.6K
48.19K
-25K
-$25K
9-12 Months
5.2M
335.42K
77.3K
225.35K
+110K
+$110K
Top Buyers
Fain Eric S
Director
$216K
Hochman David P
Director, Officer: See Remarks
$171K
Aryeh Jason
Director
$158K
Sherman Darren
Director, Officer: See Remarks
$8K
Taylor Andrew Lawrence
Officer: Chief Financial Officer
$5K
Top Sellers
Sherman Darren
Director, Officer: See Remarks
$168K
Taylor Andrew Lawrence
Officer: Chief Financial Officer
$128K
Hochman David P
Director, Officer: See Remarks
$26K
Fain Eric S
Director
$8K
Aiello Joshua
Officer: Principal Accounting Officer
$2K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $227K net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
SEC Filings
OBIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 30, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | July 01, 2022 | July 26, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.